Floatz logo

IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS ICOS (INDUCIBLE T-CELL COSTIMULATORY, ACTIVATION-INDUCIBLE LYMPHOCYTE IMMUNOMEDIATORY MOLECULE, AILIM, CD278)) AND ANTI-(HOMO SAPIENS PDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC

Gastric or Gastroesophageal Junction Adenocarcinoma

Xencor, Inc.monoclonal_antibodyPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

41 Active assets in the Gastric or Gastroesophageal Junction Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
Pembrolizumab
Diwakar Davar
Phase 3BB
Nivolumab
Memorial Sloan Kettering Cancer Center
Phase 2BB
TRASTUZUMAB
UNICANCER
Phase 3BB
LENVATINIB
Merck Sharp & Dohme LLC
Phase 3B

View all 50 →

Same molecule, other indications

IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS ICOS (INDUCIBLE T-CELL COSTIMULATORY, ACTIVATION-INDUCIBLE LYMPHOCYTE IMMUNOMEDIATORY MOLECULE, AILIM, CD278)) AND ANTI-(HOMO SAPIENS PDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC is also rated in:

triple-negative breast carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
cutaneous melanomaDormant
CC
Indicative ·
47 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →